Skip to content

Christian Heinis

Christian Heinis

Chemical Sciences and Engineering, EPFL

About Christian Heinis

Christian Heinis studied biochemistry at the Swiss Federal Institute of Technology in Zurich (ETH). After a PhD in the research group of Prof. Dr. Dario Neri at ETH, he did two post-docs, the first one with Prof. Dr. Kai Johnsson at the Ecole Polytechnique Fédéral de Lausanne (EPFL) and the second one with Sir Gregory Winter at the Laboratory of Molecular Biology (LMB) in Cambridge, UK. In 2008 he started as Assistant Professor at EPFL (supported with an SNSF professorship) and was promoted in 2015 to Associate Professor. He is co-Director of the NCCR Chemical Biology, member of the NCCR Steering Committee and the NCCR Education Committee..

His research aims at developing therapeutics based on peptide macrocycles using novel biological and chemical tools. An important activity of his laboratory is the generation of antagonists based on bicyclic peptides by phage display. Christian is a scientific co-founder of the start-up company Bicycle Therapeutics.

Read more about Christian Heinis’s research on his lab website.


Ecole polytechnique fédérale de Lausanne
Institut des sciences et ingénierie chimiques
BCH 5305 (Bâtochime)
1015 Lausanne, Switzerland
Phone: +41 (0)21 693 93 50


Sevan Habeshian, Ganesh A. Sable, Mischa Schüttel, Manuel L. Merz, Christian Heinis, “Cyclative Release Strategy to Obtain Pure Cyclic Peptides Directly from the Solid Phase”, ACS Chem. Biol. 2022, 17, 1, 181–186. [More Information]

Ganesh Kumar Mothukuri, Sangram S Kale, Carl Leonard Stenbratt, Alessandro Zorzi, Jonathan Vesin, Julien Bortoli Chapalay, Kaycie Deyle, Gerardo Turcatti, Laura Cendron, Alessandro Angelini and Christian Heinis, “Macrocycle synthesis strategy based on step-wise “adding and reacting” three components enables screening of large combinatorial libraries”, Chem. Sci., 11, 7858-7863, 2020. Open access [More Information]

Khan Maola, Jonas Wilbs, Jeremy Touati, Michal Sabisz, Xu‐Dong Kong, Alice Baumann, Kaycie Deyle, Christian Heinis, “Engineered peptide macrocycles can inhibit matrix metalloproteinases with high selectivity”, Ang. Chemie, vol. 58, issue 34, 2019. Free access [More Information]

Kale S.S., Bergeron-Brlek M., Wu Y., Kumar M.G., Pham M.V., Bortoli J., Vesin J., Kong X.D., Machado J.F., Deyle K., Gonschorek P., Turcatti G., Cendron L., Angelini A., Heinis C., “Thiol-to-amine cyclization reaction enables screening of large libraries of macrocyclic compounds and the generation of sub-kilodalton ligands”, Science Advances, 5, eaaw2851. Open access [More Information]

Sangram S. Kale, Camille Villequey, Xu-Dong Kong, Alessandro Zorzi,Kaycie Deyle & Christian Heinis, “Cyclization of peptides with two chemical bridges affords large scaffold diversities”, Nature Chemistry, 30 April 2018. DOI: 10.1038/s41557-018-0042-7. [More Information]

Rentero Rebollo I., McCallin S., Bertoldo D., Entenza J., Moreillon P. and Heinis C., “Development of potent and selective S. Aureus sortase A inhibitors based on peptide macrocycles”, ACS Medicinal Chemistry Letters, 7(6), 606-11, (2016). [More Information]

Diderich P., Bertoldo D., Dessen P., Khan M.M., Pizzitola I., Held W., Huelsken J. and Heinis C., “Phage selection of chemically stabilized alpha-helical peptide ligands”, ACS Chemical Biology, 11(5), 1422-7, (2016). [More Information]

Baeriswyl V., Calzavarini S., Chen S., Zorzi A., Bologna L., Angelillo-Scherrer A., and Heinis C. “A synthetic factor XIIa inhibitor blocks selectively intrinsic coagulation initiation”, ACS Chemical Biology, (2015). [More Information]

Rentero Rebollo I., Sabisz M., Baeriswyl V. and Heinis C., “Identification of target-binding peptide motifs by high-throughput sequencing of phage-selected peptides”, Nucleic Acids Research, (2015). [More Information]

Pollaro L., Raghunathan S., Morales-Sanfrutos J., Angelini A., Kontos S. and Heinis C. “Bicyclic peptides conjugated to an albumin-binding tag diffuse efficiently into solid tumors”, Molecular Cancer Therapeutics, 14, 151-61, (2014). [More Information]